What the FDA labels say about taking them together
Simvastatin and voriconazole
Simvastatin's FDA label of March 28, 2025 names voriconazole in its drug interactions section; voriconazole's label does not name simvastatin itself but warns about its class (Statins). The simvastatin label: “Simvastatin is a substrate of CYP3A4. Concomitant use of strong CYP3A4 inhibitors with ZOCOR increases simvastatin exposure and increases the risk of myopathy and rhabdomyolysis, particularly with higher ZOCOR dosages.”
Check it at the source: the simvastatin FDA label on DailyMed (effective March 28, 2025, Organon LLC); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the simvastatin label say about voriconazole?
Simvastatin label, drug interactionsStrong CYP3A4 inhibitors Clinical Impact: Simvastatin is a substrate of CYP3A4. Concomitant use of strong CYP3A4 inhibitors with ZOCOR increases simvastatin exposure and increases the risk of myopathy and rhabdomyolysis, particularly with higher ZOCOR dosages. … inhibitor treatment. Examples: Select azole anti-fungals (e.g., itraconazole, ketoconazole, posaconazole, and voriconazole), select macrolide antibiotics (e.g., erythromycin and clarithromycin), select HIV protease inhibitors (e.g., nelfinavir, ritonavir, and darunavir/ritonavir), select HCV protease …
Source: FDA drug label (ZOCOR), Organon LLC, effective March 28, 2025 (SPL set 8f55d5de-5a4f-4a39-8c84-c53976dd6af9), via openFDA; the full label on DailyMed
What does the voriconazole label say about simvastatin?
Voriconazole's label does not name simvastatin itself; it warns about its class (Statins):
Voriconazole label, drug interactionsHMG-CoA Reductase Inhibitors (Statins) (CYP3A4 Inhibition) In Vitro Studies Demonstrated Potential for Voriconazole to Inhibit Metabolism (Increased Plasma Exposure) Frequent monitoring for adverse reactions and toxicity related to statins.
Voriconazole label, drug interactionsIncreased statin concentrations in plasma have been associated with rhabdomyolysis.
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Simvastatin | Voriconazole | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, High cholesterol, High triglycerides | Fungal infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0321 per tablet 20 mg tablet | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once